ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
STAT1: a central hub linking ferroptosis and inflammation in hepatic ischemia-reperfusion injury.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatic ischemia-reperfusion injury (HIRI) remains an intractable perioperative complication of liver transplantation and hepatectomy, driven by two interdependent but historically segregated pathological cascades: iron-dependent ferroptotic parenchymal death and amplified sterile inflammatory signaling. A critical unmet gap in the field is identification of a single upstream molecular node capable of synchronously coordinating both injury programs. Building upon the foundational murine experimental work published by Wu et al. (2025) defining the STAT1-miR-497-5p-HDAC7 linear signaling cascade, this Perspective advances three exclusive, integrative conceptual frameworks original to our group: (1) STAT1 functions as a convergent master transcriptional hub that epigenetically couples ferroptosis and inflammation via one unified epigenetic axis; (2) the STAT1-miR-497-5p-HDAC7 module represents a conserved universal pathogenic cassette across all solid organ ischemia-reperfusion injury (IRI); (3) a tiered tri-modal translational pipeline integrating combinatorial circulating biomarkers, selective small-molecule HDAC7/JAK inhibitors, and tissue-targeted miR-497-5p RNA therapeutics enables dual-action liver graft protection. Beyond synthesizing published mechanistic data, we reframe field-wide generic HIRI research bottlenecks into STAT1-axis-specific testable hypotheses, including compartmentalized cell-type synergistic injury loops, estrogen-driven sexual dimorphism of STAT1 epigenetic activity, and closed bidirectional feedback circuits between STAT1 and canonical IRI pathways (NF-κB, Nrf2, HIF-1α). We further outline a cell-specific knockout and single-cell transcriptomic experimental roadmap to validate our novel predictions, and contextualize near-term clinical translation of this axis for perioperative liver protection. Targeted disruption of this STAT1-centered regulatory hub represents a uniquely promising strategy to simultaneously block both ferroptotic and inflammatory liver damage, with broad translatable implications for multi-organ IRI treatment.
Indexed as
Identifiers
42752934What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.